Evidence map›Paper›PMID 24023368›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2013

Pharmacological inhibition of pleckstrin homology domain leucine-rich repeat protein phosphatase is neuroprotective: differential effects on astrocytes.

Travis C Jackson, Jonathan D Verrier, Tomas Drabek, Keri Janesko-Feldman, Delbert G Gillespie, Thomas Uray, Cameron Dezfulian, Robert S Clark, Hülya Bayir, Edwin K Jackson and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. PHLPP is neither a Phosphatase nor a Tumor Suppressor.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Pleckstrin homology (PH) domain and Leucine Rich Repeat Phosphatase 1 (Phlpp1) Suppresses Parathyroid Hormone Receptor 1 (Pth1r) Expression and Signaling During Bone Growth.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Travis C JacksonUniversity of Pittsburgh School of Medicine, Department of Critical Care Medicine, Safar Center for Resuscitation Research (T.C.J., P.M.K., H.B., R.S.C, K.J.F., C.D., T.U.) and Department of Pharmacology and Chemical Biology (J.D.V., D.G.G., E.K.J.),University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and Department of Anesthesiology, Presbyterian Hospital (T.D.), Pittsburgh, Pennsylvania.
Jonathan D Verrier
Tomas Drabek
Keri Janesko-Feldman
Delbert G Gillespie
Thomas Uray
Cameron Dezfulian
Robert S Clark
Hülya Bayir
Edwin K Jackson
Patrick M Kochanek
University of Pittsburgh · USUPMC Presbyterian · US

Funding

Single Nephron and MetabolomicsP30DK079307 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KLEYMAN, THOMAS R · 2008 to 2022
$13.4M
Nitrite based neuroprotection after cardiac arrestK08NS069817 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEZFULIAN, CAMERON · 2010 to 2014
$842k
NIDDK NIH HHS DK079307NIDDK NIH HHS P30 DK079307NINDS NIH HHS K08 NS069817NINDS NIH HHS K08-NS069817
6 · The paper itself

Abstract

Pleckstrin homology domain and leucine-rich repeat protein phosphatase 1 (PHLPP1) inhibits protein kinase B (AKT) survival signaling in neurons. Small molecule pan-PHLPP inhibitors (selective for PHLPP1 and PHLPP2) may offer a translatable method to induce AKT neuroprotection. We tested several recently discovered PHLPP inhibitors (NSC117079 and NSC45586; benzoic acid, 5-[2-[4-[2-(2,4-diamino-5-methylphenyl)diazenyl]phenyl]diazenyl]-2-hydroxy-,sodium salt.) in rat cortical neurons and astrocytes and compared the biochemical response of these agents with short hairpin RNA (shRNA)-mediated PHLPP1 knockdown (KD). In neurons, both PHLPP1 KD and experimental PHLPP inhibitors activated AKT and ameliorated staurosporine (STS)-induced cell death. Unexpectedly, in astrocytes, both inhibitors blocked AKT activation, and NSC117079 reduced viability. Only PHLPP2 KD mimicked PHLPP inhibitors on astrocyte biochemistry. This suggests that these inhibitors could have possible detrimental effects on astrocytes by blocking novel PHLPP2-mediated prosurvival signaling mechanisms. Finally, because PHLPP1 levels are reportedly high in the hippocampus (a region prone to ischemic death), we characterized hippocampal changes in PHLPP and several AKT targeting prodeath phosphatases after cardiac arrest (CA)-induced brain injury. PHLPP1 levels increased in rat brains subjected to CA. None of the other AKT inhibitory phosphatases increased after global ischemia (i.e., PHLPP2, PTEN, PP2A, and PP1). Selective PHLPP1 inhibition (such as by shRNA KD) activates AKT survival signaling in neurons and astrocytes. Nonspecific PHLPP inhibition (by NSC117079 and NSC45586) only activates AKT in neurons. Taken together, these results suggest that selective PHLPP1 inhibitors should be developed and may yield optimal strategies to protect injured hippocampal neurons and astrocytes-namely from global brain ischemia.

Indexed as

AnimalsAnthraquinonesAstrocytesAzo CompoundsBrain IschemiaCell Culture TechniquesCell SurvivalDose-Response Relationship, DrugHeart ArrestHEK293 CellsHumansMolecular StructureNeuronsNeuroprotective AgentsNuclear ProteinsPhenylenediaminesAnthraquinonesAzo CompoundsNeuroprotective AgentsNSC117079NSC45586Nuclear ProteinsPhenylenediaminesPHLPP1 protein, ratProto-Oncogene Proteins c-aktSulfonamides

Identifiers

PMID24023368
PMCPMC3807060
OpenAlexW1973881801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.